...
首页> 外文期刊>Open Heart >Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS)
【24h】

Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS)

机译:先前进行非ST段抬高的急性冠状动脉综合征的冠状动脉搭桥手术患者的非侵入性与侵入性管理:飞行员随机对照试验和注册表(CABG-ACS)的研究设计

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction There is an evidence gap about how to best treat patients with prior coronary artery bypass grafts (CABGs) presenting with non-ST segment elevation acute coronary syndromes (NSTE-ACS) because historically, these patients were excluded from pivotal randomised trials. We aim to undertake a pilot trial of routine non-invasive management versus routine invasive management in patients with NSTE-ACS with prior CABG and optimal medical therapy during routine clinical care. Our trial is a proof-of-concept study for feasibility, safety, potential efficacy and health economic modelling. We hypothesise that a routine invasive approach in patients with NSTE-ACS with prior CABG is not superior to a non-invasive approach with optimal medical therapy. Methods and analysis 60 patients will be enrolled in a randomised clinical trial in 4 hospitals. A screening log will be prospectively completed. Patients not randomised due to lack of eligibility criteria and/or patient or physician preference and who give consent will be included in a registry. We will gather information about screening, enrolment, eligibility, randomisation, patient characteristics and adverse events (including post-discharge). The primary efficacy outcome is the composite of all-cause mortality, rehospitalisation for refractory ischaemia/angina, myocardial infarction and hospitalisation for heart failure. The primary safety outcome is the composite of bleeding, stroke, procedure-related myocardial infarction and worsening renal function. Health status will be assessed using EuroQol 5 Dimensions (EQ-5D) assessed at baseline and 6 monthly intervals, for at least 18?months. Trial registration number NCT01895751 (ClinicalTrials.gov).
机译:引言关于如何最好地治疗先前患有非ST段抬高的急性冠状动脉综合征(NSTE-ACS)的先前冠状动脉旁路移植术(CABG)的患者,尚存在证据空白,因为历史上,这些患者被排除在关键性随机试验之外。我们的目标是对先行CABG并在常规临床护理期间进行最佳药物治疗的NSTE-ACS患者进行常规无创治疗与常规有创治疗的试验性试验。我们的试验是关于可行性,安全性,潜在功效和健康经济模型的概念验证研究。我们假设在NSTE-ACS合并CABG的患者中采用常规侵入性治疗方法并不优于采用最佳药物治疗的非侵入性治疗方法。方法和分析60例患者将被纳入4家医院的随机临床试验中。筛选日志将有望完成。由于缺乏资格标准和/或患者或医生的喜好而没有随机分组并给予同意的患者将被纳入注册表。我们将收集有关筛查,入组,资格,随机化,患者特征和不良事件(包括出院后)的信息。主要疗效结果是全因死亡率,难治性局部缺血/心绞痛的住院治疗,心肌梗塞和心力衰竭住院的综合结果。主要安全结果是出血,中风,与手术相关的心肌梗塞和肾功能恶化的综合症状。健康状况将使用EuroQol 5 Dimensions(EQ-5D)进行评估,至少在基线期和六个月间隔内评估至少18个月。试用注册号NCT01895751(ClinicalTrials.gov)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号